Authors
Latest:
Challenges With Targeted Therapies in Ovarian CancerBrian Burgess, DO, PhD, a first-year fellow at the University of Kentucky, discusses the biggest challenge with targeted therapies in ovarian cancer. PARP resistance has become a huge barrier in this treatment paradigm.
Latest:
Revlimid Plus Dexamethasone Versus Standard Treatment for Multiple MyelomaBrian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses results from a phase III trial that compared lenalidomide (Revlimid) plus dexamethasone versus the standard treatment of melphalan plus prednisone and thalidomide (MPT) in patients with multiple myeloma who are over 65 years old. Durie offers his thoughts regarding the impact of this trial.
Latest:
Prevention of Cytomegalovirus After Allogeneic HSCTTwo poster presentations at the 2018 BMT Tandem Meetings of the Center for International Blood & Marrow Transplant Research and the American Society for Blood and Marrow Transplantation, provided a compelling extension of the recent phase III clinical trial that demonstrated the efficacy of prophylactic therapy with letermovir (Prevymis) for the prevention of cytomeg alovirus (CMV) infection in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT).
Latest:
First-Line Treatment for Advanced Clear Cell RCC: Key TakeawaysClosing out their discussion on advanced RCC, expert hematologist/oncologists offer key takeaways from their discussion and look toward future treatment evolution in the first-line setting.
Latest:
Results of the SWOG S0500 TrialBrian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the results of the SWOG S0500 trial, which looked at circulating tumor cell (CTC) levels in patients with metastatic breast cancer.
Latest:
Dr. Brian Nussenbaum on the Difficulties of Improving Survival in Larynx CancerNussenbaum says the current balance in the treatment paradigm of larynx cancer is between surreal and cure, all while maintaining a functional preservation for the patient.
Latest:
Unmet Needs and Future Outlook in aRCC TreatmentThe panel explores unmet needs in aRCC treatment and shares expectations for changes and advances in the landscape in the near future.
Latest:
Evolving Role of CAR T-Cell Therapy in Mantle Cell LymphomaBrian Hill, MD, discusses the use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma and identifies other novel agents in this setting.
Latest:
Dr. Van Tine Discusses the Development of Olaratumab in SarcomaBrian Van Tine, MD, PhD, assistant professor, Washington University School of Medicine, discusses the development of olaratumab (Lartruvo) in soft tissue sarcoma.
Latest:
Results of a Phase II Study of LHRH Therapy in High-Risk Prostate CancerBridget F. Koontz, MD, associate professor of radiation oncology, Duke Cancer Institute, discusses a single-arm, phase II trial of 6 months of concurrent androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.
Latest:
Genomic Profiling Provides Much-Needed Prognostic Data in GliomaResults from a genomic and molecular analysis presented at the 2015 ASCO Annual Meeting and published in Acta Neuropathology indicate that low-grade gliomas may be classified into three distinct prognostic categories based on genomic data.
Latest:
HRRm Tester Underutilized for mCRPC in the Real-World SettingWhile germline and somatic testing is standard of care in the metastatic castration-resistant prostate cancer setting, it is still underutilized in the real world, leading to negative impacts on therapeutic offerings.
Latest:
Expert Discusses Long-Term Efficacy of Pembrolizumab in MelanomaEric Whitman, MD, discusses data for pembrolizumab in the frontline treatment of advanced melanoma and ongoing research with the agent in other settings of the disease.
Latest:
Novel Treatment Strategies Are Explored in Pancreatic CancerOutcomes in pancreatic cancer may be improving for the first time in decades. With pancreatic cancer projected to be the second leading cause of cancer-related deaths in the United States by the year 2030,1 this projection brings welcome optimism to the field.
Latest:
Early Activity With Frontline Sacituzumab Govitecan/Pembro in Metastatic NSCLCIn patients with metastatic non–small cell lung cancer given sacituzumab govitecan-hziy with pembrolizumab, positive response rates were observed.
Latest:
Using the LGR5 Protein as a Biomarker in Thyroid CancerBrittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.
Latest:
Dr. O'Neil Discusses Robotic Prostatectomy Versus Open SurgeryBrock O'Neil, MD, physician instructor in urologic surgery, Vanderbilt University, discusses robotic prostatectomy versus open surgery.
Latest:
The Mechanism of Action and Use of Antibody Drug ConjugatesBruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, describes the mechanism of action of antibody drug conjugates and their use.
Latest:
The Significance of the RESORCE Trial in HCCBruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the significance of the RESORCE trial, which examined the use of regorafenib (Stivarga) as a treatment for patients with hepatocellular carcinoma (HCC).
Latest:
Engineering Chimeric Antigen Receptor T Cells to Treat GlioblastomaThe authors share their experience with EGFRvIII-specific chimeric antigen receptors, which they hope will contribute to the growing body of research committed to discovering a novel therapy for glioblastoma.
Latest:
Anti-Androgen Not for Male Cancers AloneA potential pathogenic role for the androgen receptor (AR) exists for some breast cancer (BC) subtypes according to 2 new studies presented at the San Antonio Breast Cancer Symposium (SABCS) 2014.
Latest:
Tropomyosin-Related Kinases (TRK) Making Headway in Head and Neck CancerTreatment of certain head and neck cancers may soon be fundamentally transformed through the use of molecular diagnostics to dissect essential oncogenic driver pathways, and ultimately to identify targeted therapies that specifically inhibit them.
Latest:
Exploring the Future of CAR T-Cell Therapy in Multiple MyelomaC. Ola Landgren, MD, PhD, discusses what is next for chimeric antigen receptor T-cell therapy in the multiple myeloma landscape.
Latest:
New Options Possible in Patients With NSCLC and Brain MetastasesA study published in the Journal of Clinical Oncology found that an EGFR inhibitor, erlotinib, was well tolerated in combination with whole-brain radiation therapy for patients with brain metastases from NSCLC.
Latest:
The Design of a Chimeric Antigen ReceptorCameron J. Turtle, MD, PhD, from the Fred Hutchinson Cancer Research Center, discusses the design of a chimeric antigen receptor (CAR).
Latest:
The Relationship Between CAR-Modified CD4 and CD8 T Cells in B-Cell MalignanciesCameron J. Turtle, MD, PhD, discuses the relationship between CD4 and CD8 T cells in patients with B-cell malignancies.
Latest:
Dr. Carey Anders on Exclusion of Patients With Brain Metastases From Clinical TrialsCarey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, discusses the exclusion of patients with breast cancer who have developed brain metastases from clinical trials.
